nMET, A New Target in Recurrent Cancer

Author(s): Yingqiu Xie, Sholpan Istayeva, Zhanlin Chen, Tursonjan Tokay, Zhaxybay Zhumadilov, Denglong Wu, Gonzalo Hortelano, Jinfu Zhang

Journal Name: Current Cancer Drug Targets

Volume 16 , Issue 7 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


Membranous Met is classically identified with its role in cancer metastases, while nuclear Met is associated with a more invasive, aggressive and proliferative form of cancer. Full-length Met or N-terminal transmembrane domain cleaved Met can translocate into nucleus in a cell growth and pH dependent but both ligand-dependent (full length Met) and -independent (cleaved Met) manner. nMET may play greater essential roles in cancer recurrence than membranous Met. For example, in prostate cancer, it has been found that androgen receptor (AR) may inhibit the expression of membranous Met so anti-androgen based prostate cancer therapy may promote the expression of nuclear Met (nMET). We recently found a novel nMET/SOX9/ β-Catenin/AR pathway in relapsed prostate cancer which may contribute to the formation of the feedback loop of AR reactivation via MET/nMET. Emerging evidence suggests the possibility of nMET as a prognostic marker in relapsed cancer. This review summarizes recent findings about nMET and its unique role in recurrent cancer.

Keywords: Met, nuclear translocation, oncogene, recurrence.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [572 - 578]
Pages: 7
DOI: 10.2174/1568009616666160105105250
Price: $65

Article Metrics

PDF: 38